Engineering antibodies for dual specificity and enhanced potency
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정상택 | - |
dc.date.accessioned | 2022-04-10T18:40:20Z | - |
dc.date.available | 2022-04-10T18:40:20Z | - |
dc.date.created | 2022-04-08 | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 1226-8372 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/139927 | - |
dc.description.abstract | Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING | - |
dc.title | Engineering antibodies for dual specificity and enhanced potency | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 정상택 | - |
dc.identifier.doi | 10.1007/s12257-014-0575-6 | - |
dc.identifier.bibliographicCitation | BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, v.20, no.2, pp.201 - 210 | - |
dc.relation.isPartOf | BIOTECHNOLOGY AND BIOPROCESS ENGINEERING | - |
dc.citation.title | BIOTECHNOLOGY AND BIOPROCESS ENGINEERING | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 201 | - |
dc.citation.endPage | 210 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | antibody engineering | - |
dc.subject.keywordAuthor | bispecific antibody | - |
dc.subject.keywordAuthor | dual specificity | - |
dc.subject.keywordAuthor | therapeutic antibody | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.